Functional response, in T2 severe asthmatic patients, treated with mepolizumab for 2 years

Key Points

• To evaluate the functional response to mepolizumab in patients with severe asthma over a two-year period.
• Assessed functional response through FEV1 measurements.
• Monitored patients treated with mepolizumab for two years.
• Evaluated changes in pharmacologic treatment, particularly corticosteroids.
• FEV1 increases were detectable within the first two months of treatment.
• Functional improvements were sustained over the two years of therapy.
• Systemic corticosteroid use was progressively reduced during the treatment period.